JP5827220B2 - 人工多能性幹細胞の樹立効率改善方法 - Google Patents

人工多能性幹細胞の樹立効率改善方法 Download PDF

Info

Publication number
JP5827220B2
JP5827220B2 JP2012513400A JP2012513400A JP5827220B2 JP 5827220 B2 JP5827220 B2 JP 5827220B2 JP 2012513400 A JP2012513400 A JP 2012513400A JP 2012513400 A JP2012513400 A JP 2012513400A JP 5827220 B2 JP5827220 B2 JP 5827220B2
Authority
JP
Japan
Prior art keywords
myc
human
cells
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012513400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517758A (ja
JP2013517758A5 (enExample
Inventor
伸弥 山中
伸弥 山中
誠人 中川
誠人 中川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JP2013517758A publication Critical patent/JP2013517758A/ja
Publication of JP2013517758A5 publication Critical patent/JP2013517758A5/ja
Application granted granted Critical
Publication of JP5827220B2 publication Critical patent/JP5827220B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012513400A 2010-01-22 2011-01-21 人工多能性幹細胞の樹立効率改善方法 Active JP5827220B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28232010P 2010-01-22 2010-01-22
US61/282,320 2010-01-22
PCT/JP2011/051685 WO2011090221A1 (en) 2010-01-22 2011-01-21 Method for improving induced pluripotent stem cell generation efficiency

Publications (3)

Publication Number Publication Date
JP2013517758A JP2013517758A (ja) 2013-05-20
JP2013517758A5 JP2013517758A5 (enExample) 2014-03-06
JP5827220B2 true JP5827220B2 (ja) 2015-12-02

Family

ID=44307020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012513400A Active JP5827220B2 (ja) 2010-01-22 2011-01-21 人工多能性幹細胞の樹立効率改善方法

Country Status (4)

Country Link
US (1) US9005967B2 (enExample)
EP (1) EP2526189B1 (enExample)
JP (1) JP5827220B2 (enExample)
WO (1) WO2011090221A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349446C1 (en) 2010-12-22 2016-01-21 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
EP2951290B1 (en) 2013-02-01 2017-11-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
WO2014124087A1 (en) 2013-02-06 2014-08-14 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
CA2997763A1 (en) 2015-09-08 2017-03-16 Cellular Dynamics International, Inc. Macs-based purification of stem cell-derived retinal pigment epithelium
KR102781602B1 (ko) 2015-09-08 2025-03-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 임상 등급 망막 색소 상피 세포의 재현성 있는 분화 방법
CA3001917A1 (en) 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
ES2862676T3 (es) 2015-10-20 2021-10-07 Fujifilm Cellular Dynamics Inc Producción de células precursoras hematopoyéticas multilinaje mediante programación genética
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
US11866733B2 (en) 2016-08-01 2024-01-09 University of Pittsburgh—of the Commonwealth System of Higher Education Human induced pluripotent stem cells for high efficiency genetic engineering
EP3523422B1 (en) 2016-10-05 2024-12-25 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
AU2017359330B2 (en) 2016-11-09 2022-03-10 The United States Of America, As Represented By The Secretary Department Of Health And Human Services 3D vascularized human ocular tissue for cell therapy and drug discovery
EP3583201B1 (en) 2017-02-14 2024-01-17 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
AU2018254442B2 (en) 2017-04-18 2024-03-28 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
JP7457505B2 (ja) 2017-05-10 2024-03-28 ユニバーシティー オブ ロチェスター 神経精神障害を処置する方法
AU2019256723B2 (en) 2018-04-20 2025-09-04 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
CA3103663A1 (en) 2018-06-18 2019-12-26 University Of Rochester Inhibition of re1-silencing transcription factor in the treatment of schizophrenia and other neuropsychiatric disorders
KR20210054502A (ko) 2018-06-21 2021-05-13 유니버시티 오브 로체스터 헌팅턴병을 치료하거나 이의 발병을 저해하는 방법
JP7718819B2 (ja) * 2018-07-02 2025-08-05 リン、シー－ラン 成体幹細胞の拡大と誘導のインビトロでの誘発
IL282791B2 (en) 2018-11-19 2026-03-01 Us Health Biodegradable tissue replacement implant and its use
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
CA3122289A1 (en) 2018-12-11 2020-06-18 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
WO2020167822A2 (en) 2019-02-13 2020-08-20 University Of Rochester Gene networks that mediate remyelination of the human brain
AU2021235185A1 (en) 2020-03-09 2022-11-03 Fujifilm Corporation Markers specific for pluripotent stem cells, and methods of using the same
BR112022024064A2 (pt) 2020-05-29 2023-01-31 Fujifilm Cellular Dynamics Inc Bicamada de epitélio pigmentado da retina e fotorreceptores e uso dos mesmos
PH12022552993A1 (en) 2020-05-29 2023-01-16 Fujifilm Cellular Dynamics Inc Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021381011B2 (en) 2020-11-18 2025-04-10 Assistance Publique - Hopitaux De Paris Generation of secretome-containing compositions, and methods of using and analyzing the same
CA3199729A1 (en) 2020-11-24 2022-06-02 Monash University Induced stem cells
CA3199728A1 (en) 2020-11-24 2022-06-02 Jose POLO Methods and cellular structures
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
IL306134A (en) 2021-03-25 2023-11-01 Bluerock Therapeutics Lp Methods for obtaining induced pluripotent stem cells
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
ES3064924T3 (en) 2021-05-28 2026-04-30 Us Health Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells
JP2024520424A (ja) 2021-05-28 2024-05-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 黄斑、中心および末梢網膜色素上皮細胞を生成する方法
EP4402249A1 (en) 2021-09-13 2024-07-24 Fujifilm Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
CA3235105A1 (en) 2021-10-20 2023-04-27 Steven A. Goldman Humanized chimeras for the prospective assessment of glial cell addition or replacement therapy
WO2023069881A1 (en) 2021-10-20 2023-04-27 University Of Rochester Treatment with genetically modified cells, and genetically modified cells per se, with increased competitive advantage and/or decreased competitive disadvantage
AU2022368907A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Rejuvenation treatment of age-related white matter loss
US20230270818A1 (en) 2021-11-02 2023-08-31 University Of Rochester Tcf7l2 mediated remyelination in the brain
EP4472648A1 (en) 2022-02-01 2024-12-11 University of Rochester Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
WO2023215455A1 (en) 2022-05-05 2023-11-09 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
WO2024006911A1 (en) 2022-06-29 2024-01-04 FUJIFILM Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
US20240139256A1 (en) 2022-09-30 2024-05-02 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
EP4658294A2 (en) 2023-02-02 2025-12-10 University of Rochester Competitive replacement of glial cells
WO2024192329A1 (en) 2023-03-16 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for producing stable human chondroctyes and their use for promoting cartillage growth and repair
WO2025245202A1 (en) 2024-05-21 2025-11-27 FUJIFILM Cellular Dynamics, Inc. Particle counting and biomass measurements of aggregated cell compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US6255112B1 (en) 1998-06-08 2001-07-03 Osiris Therapeutics, Inc. Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
ATE367445T1 (de) 1999-05-18 2007-08-15 Dnavec Research Inc Viraler paramyxoviridae vektor mit einem defekten hüllprotein-gen
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
JP3660601B2 (ja) 2001-03-30 2005-06-15 独立行政法人科学技術振興機構 胚性幹細胞からの神経幹細胞、運動ニューロン及びｇａｂａ作動性ニューロンの製造法
JP2004121165A (ja) 2002-10-07 2004-04-22 Asahi Kasei Corp 膵幹様細胞の分化誘導方法
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
EP3399025B1 (en) 2007-03-23 2025-05-07 Wisconsin Alumni Research Foundation Somatic cell reprogramming
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method

Also Published As

Publication number Publication date
US20120276636A1 (en) 2012-11-01
EP2526189A4 (en) 2014-03-19
US9005967B2 (en) 2015-04-14
WO2011090221A1 (en) 2011-07-28
JP2013517758A (ja) 2013-05-20
EP2526189B1 (en) 2016-10-12
EP2526189A1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
EP2526189B1 (en) Method for improving induced pluripotent stem cell generation efficiency
JP5765746B2 (ja) 効率的な人工多能性幹細胞の樹立方法
JP5553289B2 (ja) 新規核初期化物質
JP5888753B2 (ja) 効率的な人工多能性幹細胞の樹立方法
US9506039B2 (en) Efficient method for establishing induced pluripotent stem cells
US20110003365A1 (en) Method of preparing induced pluripotent stem cells deprived of reprogramming gene
KR101564044B1 (ko) 핵초기화 방법
JP5773393B2 (ja) 効率的な人工多能性幹細胞の樹立方法
WO2011055851A1 (en) Method of efficiently establishing induced pluripotent stem cells
WO2011158967A1 (en) Method for efficiently establishing induced pluripotent stem cell
WO2013031826A1 (ja) 核初期化物質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151015

R150 Certificate of patent or registration of utility model

Ref document number: 5827220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250